WO2000033851A1 - Peritoneal dialysis solution containing modified icodextrins - Google Patents
Peritoneal dialysis solution containing modified icodextrins Download PDFInfo
- Publication number
- WO2000033851A1 WO2000033851A1 PCT/US1999/027456 US9927456W WO0033851A1 WO 2000033851 A1 WO2000033851 A1 WO 2000033851A1 US 9927456 W US9927456 W US 9927456W WO 0033851 A1 WO0033851 A1 WO 0033851A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- starch
- solution
- peritoneal dialysis
- bonds
- formula
- Prior art date
Links
- 0 OCC(C(C*C(C(C1O)O)OC(CO)C1OC(C1O)OC(CO)CC1O)C(C(CO)O)O)O Chemical compound OCC(C(C*C(C(C1O)O)OC(CO)C1OC(C1O)OC(CO)CC1O)C(C(CO)O)O)O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Definitions
- the present invention relates generally to peritoneal dialysis and solutions for the same. More specifically, the present invention relates to the use of modified icodextrins in peritoneal dialysis solutions as an osmotic agent and as an alternative to the use of glucose as an osmotic agent.
- the present invention also relates to methods of preparing peritoneal dialysis solutions that are stable under autoclaving conditions. Dialysis provides a method for supplementing or replacing renal function in certain patients. Principally, hemodialysis and peritoneal dialysis are the two methods that are currently utilized.
- hemodialysis In hemodialysis, the patient's blood is passed through an artificial kidney dialysis machine. A membrane in the machine acts as an artificial kidney for cleansing the blood. Because it is an extracorporeal treatment that requires special machinery, hemodialysis is fraught with certain inherent disadvantages such as the availability of dialysis machines and the possibility of infection and contamination .
- peritoneal dialysis To overcome the disadvantages associated with hemodialysis, peritoneal dialysis was developed. Peritoneal dialysis utilizes the patient's own peritoneum as a semi-permeable membrane. The peritoneum is a membranous lining of the abdominopelvic walls of the body. The peritoneum is capable of acting as a natural semi -permeable membrane because of its large number of blood vessels and capillaries .
- a peritoneal dialysis solution is introduced into the peritoneal cavity utilizing a catheter. After a sufficient period of time, an exchange of solutes between the dialysate and blood is achieved. Fluid removal is achieved by providing a suitable osmotic gradient from the dialysate to the blood to permit water outflow from the blood. This allows the proper acid-base, electrolyte and fluid balance to be achieved in the blood. After an appropriate dwell period, the dialysis solution or dialysate is drained from the body through a catheter.
- Conventional peritoneal dialysis solutions contain glucose as an osmotic agent to maintain the osmotic pressure of the solution higher than the physiological osmotic pressure (about 285 mOsmol/kg) .
- Glucose is a preferred osmotic agent because it provides rapid ultrafiltration rates.
- certain disadvantages have become associated with the use of glucose.
- glucose is known to decompose to 5- hydroxymethyl - furfural (5-MHF) in an aqueous solution during autoclaving or steamed sterilization.
- 5-MHF 5- hydroxymethyl - furfural
- 5-HMF is considered to be harmful for the peritoneum (Henderson, et al . , Blood Purif . , 7:86-94 (1989))
- a substitute osmotic agent for glucose is needed.
- icodextrins capable of serving as osmotic agents in peritoneal dialysis solutions
- maltodextrins One family of compounds capable of serving as osmotic agents in peritoneal dialysis solutions.
- these compounds are also known to degrade during heat sterilization to aldonic acids and formaldehyde. Because the presence of formaldehyde in peritoneal dialysis solutions is inappropriate due to its poor biocompatibility, the use of icodextrins, including maltodextrins as a substitute for glucose as an osmotic agent is unsatisfactory. Accordingly, there is a need for an improved peritoneal dialysis solution which utilizes an osmotic agent other than glucose and which is stable under autoclaving or steam sterilization conditions.
- the present invention provides a solution to the aforenoted need by providing a sterilized peritoneal dialysis solution comprising a glucose polymer linked predominately by ⁇ -1,4 bonds.
- a glucose polymer linked predominately by ⁇ -1,4 bonds includes at least 85%, by number, ⁇ -1,4 bonds.
- the glucose polymer linked predominately by ⁇ -1,4 bonds is selected from the group consisting of D-glucitol having the formula
- R is selected from the group consisting of CH 3 , CH 3 CH 2 and (CH 2 OH) 2 CH, CH 2 (OH) CH (OH) CH 2 , and (CH 2 OH) (CHOHCH 2 OH)CH.
- the glucose polymers, linked predominately by ⁇ -1,4 linkages, of the peritoneal dialysis solution may include up to 10% of other linkages including, but not limited to, ⁇ -1,6 linkages .
- the peritoneal dialysis solution of the present invention is substantially free of formaldehyde .
- the peritoneal dialysis solution of the present invention is substantially free of furfurals.
- starch utilized as the osmotic agent is substantially free of terminal aldehyde groups .
- the present invention provides a method of preparing a stabilized osmotic agent of a peritoneal dialysis solution comprising the steps of providing a solution of starch dissolved in water and adding NaBH 4 to the solution of partially hydrolyzed starch to reduce the starch.
- the method of the present invention further comprises the step of purifying the reduced starch solution by passing the reduced starch solution through an anionic exchange resin.
- the dissolving and adding steps of the method of the present invention are carried out at room temperature .
- the method of the present invention further comprises the step of allowing the solution to scan for approximately 10 hours after the NaBH 4 is added to the starch solution to reduce the starch.
- the starch of the present invention is maltodextrin.
- the method of the present invention reduces maltodextrin to D-glucitol linked predominately by ⁇ -1,4 bonds and having the formula
- the present invention provides a method for preparing a stabilized osmotic agent of a peritoneal dialysis solution which comprises the steps of providing a solution of starch dissolved in water, providing a solution of NaOCl , and adding the NaOCl solution to the starch solution to oxidize the starch.
- the method of the present invention further comprises the step of purifying the oxidized starch solution by passing the oxidized starch solution through a gel permeation chromatograph.
- the oxidation of the starch is carried out at room temperature .
- the combined solutions are allowed to stand for approximately 2 hours.
- the starch is maltodextrin.
- the method of the present invention oxidizes the maltodextrin to a gluconic acid linked predominately by ⁇ -1,4 bonds and having the formula
- the maltodextrin can be oxidized electrochemically.
- the present invention provides a method of preparing a stabilized osmotic agent for a peritoneal dialysis solution which comprises the steps of dissolving the starch in an acid and an alcohol selected from the group consisting of methanol, butanol, glycerol or other alcohols.
- the method further comprises the step of stirring the starch, alcohol and acid for 2-16 hours.
- the method further comprises the step of stirring the starch, alcohol and acid at a temperature of about 100°C.
- the starch is maltodextrin.
- the acid is hydrochloric acid or other acids such as sulfuric acid.
- the method of the present invention hydrolysizes and alkylates the starch to an alkylglycoside linked predominately by ⁇ -1,4 bonds and having the formula
- R is selected from the group consisting of CH 3 , CH 3 CH 2 and (CH 2 OH) 2 CH.
- R is the remnant of a glycol-split glucose unit.
- Another advantage of the present invention is that it provides an improved osmotic agent as an alternative to glucose. Yet another advantage of the present invention is that it provides improved methods of preparing peritoneal dialysis solutions.
- Yet another advantage of the present invention is that it provides improved osmotic agents for peritoneal dialysis solutions which are stable under autoclaving or steam sterilization conditions.
- FIGURE 1 is a graphical illustration of the 13 C NMR spectrum of an osmotic agent prepared by glycosylation in accordance with the present invention.
- Figure 2 is a graphical illustration of the 13 C NMR spectrum of an osmotic agent prepared by glycosylation in accordance with the present invention.
- the present invention provides a peritoneal dialysis solution with osmotic agents that are stable under autoclaving and steam sterilization conditions.
- the stable osmotic agents of the present invention may be prepared by reduction, oxidation or glycosylation.
- an icodextrin having reducing-end units such as maltodextrin
- the reduction, oxidation or glycosylation procedures of the present invention transform the icodextrin to corresponding D- glucitols, gluconic acids and alkyglycosides respectively.
- Example 1 A reduced icodextrin was prepared by starting with 15 grams of maltodextrin dissolved in 20 ml of water. One gram of NaBH 4 was added to the solution at room temperature and the solution was allowed to stand for 10 hours. The solution was then purified by passing it through an anionic exchange resin. Three different maltodextrin starting materials were utilized. A low molecular weight (LMW) having a 3% degree of polymerization (DP) was utilized that contained 1% glucose, 37% maltose, 20% maltotetraose and 42% high molecular weight oligosaccharides .
- LMW low molecular weight
- DP 3% degree of polymerization
- HMW1 high molecular weight maltodextrin having a 14% degree of polymerization
- HMW2 high molecular weight maltodextrin with a 9% degree of polymerization containing 1% glucose, 3% maltose, 7% maltotetraose and 90% high molecular weight oliogosaccharides was utilized.
- the products and starting materials were analyzed using 13 C NMR spectroscopy . The signals associated with the reducing end units of the starting materials completely disappeared in the specter of the products. Some depolymerization was observed.
- the products were tested for stability under sterilization conditions at neutral pH. A significant reduction of absorbance variation at 284 nm ( ⁇ Abs) after sterilization is observed for the reduced compounds.
- the reduced compounds from Example 1 are listed as HMW1 red, HMW2 red and LMW red in Table 1.
- Example 2 Utilizing the three different samples of maltodextrins discussed above with respect to Example 1, oxidation reactions were carried out on each sample by dissolving 15 grams of maltodextrin in 30 ml of water and combining the starch solution with an effective amount of NaOCl in 70 ml of a solution containing sodium hydroxide and having a pH of 8 ⁇ 0.5 at a temperature of 43°C. The combined solutions were allowed to stand for approximately 2 hours and the product solution was purified by gel permeation chromatography . Again, the products were analyzed using 13 C NMR spectroscopy and were tested for stability under sterilization conditions as illustrated in Table 1. While the oxidation products, HMW1 ox HMW2 ox and LMW ox show contrasting results, this is attributed to the high molecular weight oxidized products not being completely purified.
- icodextrin were glycosylated.
- the glycosylation reactions were performed using starch as the starting material and alcohol as the alkylating agent .
- Butanol and glycerol were chosen because of their biocompatibility .
- the molecular weight of the reaction products depends upon the temperature, time and acid concentration used.
- the present invention provides a number of heat stable osmotic agents that provide a suitable substitute for glucose, improved peritoneal dialysis solutions containing stable osmotic agents as well as a variety of methods of producing improved peritoneal dialysis solutions.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002319561A CA2319561A1 (en) | 1998-12-04 | 1999-11-18 | Peritoneal dialysis solution containing modified icodextrins |
MXPA00008653A MXPA00008653A (en) | 1998-12-04 | 1999-11-18 | Peritoneal dialysis solution containing modified icodextrins. |
EP99960509A EP1051183B1 (en) | 1998-12-04 | 1999-11-18 | Peritoneal dialysis solution containing modified icodextrins |
DE69935498T DE69935498T2 (en) | 1998-12-04 | 1999-11-18 | MODIFIED ICODEXTRINE CONTAINING PERITONEAL DIOXIDE SOLUTION |
JP2000586342A JP4338317B2 (en) | 1998-12-04 | 1999-11-18 | Peritoneal dialysis solution containing modified icodextrin |
DK99960509T DK1051183T3 (en) | 1998-12-04 | 1999-11-18 | Peritoneal dialysis solution containing modified icodextrins |
AU17384/00A AU762933B2 (en) | 1998-12-04 | 1999-11-18 | Peritoneal dialysis solution containing modified icodextrins |
BR9909095-3A BR9909095A (en) | 1998-12-04 | 1999-11-18 | Peritoneal dialysis solution containing modified icodextrins |
HK01106795A HK1036014A1 (en) | 1998-12-04 | 2001-09-26 | Peritoneal dialysis solution containing modified icodextrins. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/206,063 US6770148B1 (en) | 1998-12-04 | 1998-12-04 | Peritoneal dialysis solution containing modified icodextrins |
US09/206,063 | 1998-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000033851A1 true WO2000033851A1 (en) | 2000-06-15 |
Family
ID=22764822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/027456 WO2000033851A1 (en) | 1998-12-04 | 1999-11-18 | Peritoneal dialysis solution containing modified icodextrins |
Country Status (19)
Country | Link |
---|---|
US (3) | US6770148B1 (en) |
EP (1) | EP1051183B1 (en) |
JP (3) | JP4338317B2 (en) |
KR (1) | KR100597931B1 (en) |
CN (1) | CN1150903C (en) |
AR (1) | AR021515A1 (en) |
AT (1) | ATE356627T1 (en) |
AU (1) | AU762933B2 (en) |
BR (1) | BR9909095A (en) |
CA (1) | CA2319561A1 (en) |
CO (1) | CO5150157A1 (en) |
DE (1) | DE69935498T2 (en) |
DK (1) | DK1051183T3 (en) |
ES (1) | ES2284281T3 (en) |
HK (1) | HK1036014A1 (en) |
ID (1) | ID27897A (en) |
MX (1) | MXPA00008653A (en) |
TW (1) | TW555561B (en) |
WO (1) | WO2000033851A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004022602A1 (en) * | 2002-08-16 | 2004-03-18 | Fresenius Kabi Deutschland Gmbh | Highly branched, unsubstituted or low-substituted starch products, dialysis solution and plasma expander containing the same, and the use thereof |
WO2011113608A1 (en) * | 2010-03-19 | 2011-09-22 | Fresenius Medical Care Deutschland Gmbh | Esterified polysaccharide osmotic agents |
WO2013034292A1 (en) * | 2011-09-07 | 2013-03-14 | Fresenius Medical Care Deutschland Gmbh | Pharmaceutical compositions containing carboxylated starch |
WO2016066672A1 (en) * | 2014-10-31 | 2016-05-06 | Fresenius Medical Care Deutschland Gmbh | Pharmaceutical compositions containing steviosides |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19955578C1 (en) * | 1999-11-18 | 2001-09-06 | Fresenius Medical Care De Gmbh | Multi-chamber container, with glucose concentrate compartment and hydrochloric acid concentrate compartment |
US20040121982A1 (en) * | 2002-12-20 | 2004-06-24 | Leo Martis | Biocompatible dialysis fluids containing icodextrins |
US7118857B2 (en) | 2004-02-27 | 2006-10-10 | Baxter International Inc. | Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions |
US20050276868A1 (en) * | 2004-06-10 | 2005-12-15 | Bart Degreve | Bicarbonate-based peritoneal dialysis solutions |
US8252333B2 (en) | 2006-01-26 | 2012-08-28 | Jorge Cueto-Garcia | Biodegradable, non-toxic biological adhesive for use in abdominal surgery |
US20090236284A1 (en) * | 2008-03-20 | 2009-09-24 | Baxter International Inc. | Removal of substances in dialysis solutions and dialysis components by ion exchange adsorption |
FR2945043B1 (en) * | 2009-04-30 | 2019-07-26 | Roquette Freres | PROCESS FOR PURIFYING GLUCOSE POLYMERS FOR PERITONEAL DIALYSIS SOLUTIONS |
US20140200193A1 (en) | 2011-02-08 | 2014-07-17 | Jorge Cueto García | Thixotropic biological adhesive for use in internal body cavities |
CA2839460C (en) | 2011-06-24 | 2017-08-22 | Richard W.C. LO | Multi-container systems and uses thereof |
MX350080B (en) | 2013-10-02 | 2017-08-25 | Pebisut De Mexico S A De C V | Anti-inflammatory composition for aiding and promoting the healing of chronic ulcerative lesions. |
FR3055898B1 (en) * | 2016-09-15 | 2018-11-02 | Roquette Freres | NOVEL GLUCOSE POLYMERS FOR PERITONEAL DIALYSIS |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0207676A2 (en) * | 1985-06-22 | 1987-01-07 | M L Laboratories Plc | Polymers for use in continuous peritoneal dialysis |
EP0861661A2 (en) * | 1994-01-21 | 1998-09-02 | Baxter International Inc. | Method of providing an osmotic agent for a peritoneal dialysis solution |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3878664A (en) * | 1972-11-27 | 1975-04-22 | Cybersol | Process for producing a therapeutic composition |
US3993751A (en) * | 1972-11-27 | 1976-11-23 | Cybersol, Inc. | Process for stabilizing therapeutic compositions and article |
CA1017249A (en) * | 1973-12-19 | 1977-09-13 | Chemo Drug Company | Injectable electrolyte solutions |
US3974034A (en) * | 1975-09-12 | 1976-08-10 | Cpc International Inc. | Malto-dextrins of improved stability prepared by enzymatic hydrolysis of oxidized starch |
JPS54138121A (en) | 1978-04-19 | 1979-10-26 | Nikkiso Co Ltd | Continuous production of artificial kidney dyalising solution |
DE2929871A1 (en) | 1979-07-24 | 1981-01-29 | Gambro Dialysatoren | AQUEOUS CONCENTRATE FOR DIALYSIS SOLUTIONS |
US4756838A (en) * | 1980-02-21 | 1988-07-12 | Veltman Preston Leonard | Preparation of dry dialysate products |
JPS56164113A (en) | 1980-05-21 | 1981-12-17 | Nikkiso Co Ltd | Preparation of dialysis solution |
JPS5756422A (en) | 1980-09-19 | 1982-04-05 | Iryo Kogaku Kenkyusho:Kk | Dialytic solution for artificial kidney |
US4489535A (en) | 1980-10-02 | 1984-12-25 | Veltman Preston Leonard | Materials and method for preparing dialysis solutions containing bicarbonate ions |
US4339433A (en) | 1981-01-09 | 1982-07-13 | Baxter Travenol Laboratories, Inc. | Additives for peritoneal dialysis solutions |
US4761237A (en) | 1981-07-10 | 1988-08-02 | Baxter Travenol Laboratories, Inc. | Peritoneal dialysis solution containing carbohydrate polymers |
US4879280A (en) | 1981-09-24 | 1989-11-07 | Fresenius Ag | Dialysis solution for use in intraperitoneal dialysis |
EP0076355A3 (en) | 1981-10-01 | 1983-05-25 | Abbott Laboratories | Improved peritoneal dialysis solution |
GB8300718D0 (en) | 1983-01-12 | 1983-02-16 | Milner Research Ireland Ltd | Glucose polymer solutions |
GB8404299D0 (en) | 1984-02-18 | 1984-03-21 | Milner Research Ireland Ltd | Peritoneal dialysis |
US4886789A (en) * | 1983-01-12 | 1989-12-12 | M. L. Laboratories Plc | Peritoneal dialysis and compositions for use therein |
US6077836A (en) * | 1983-01-12 | 2000-06-20 | Ml Laboratotries, Plc | Peritoneal dialysis and compositions for use therein |
JPS60166378A (en) | 1984-02-09 | 1985-08-29 | Shikoku Chem Corp | Carboxymethylated glucose polymer and method for adjusting mud using said polymer |
US4604379A (en) * | 1984-06-18 | 1986-08-05 | Curators Of The University Of Missouri | Dialysis solutions containing cross-linked gelatin |
US4663166A (en) * | 1984-06-22 | 1987-05-05 | Veech Richard L | Electrolyte solutions and in vivo use thereof |
US4668400A (en) * | 1984-06-22 | 1987-05-26 | Veech Richard L | Hemodialysis processes and hemodialysis solutions |
DE3428201A1 (en) | 1984-07-31 | 1986-02-06 | Laevosan-Gesellschaft mbH & Co. KG, Linz | PERITONEAL DIALYSIS SOLUTIONS |
JPS61247466A (en) * | 1985-04-25 | 1986-11-04 | テルモ株式会社 | Dialytic solution for abdominal membrane dialysis |
EP0209607B1 (en) | 1985-05-31 | 1989-12-20 | Hans Dr. Dietl | Hemodialysis liquid feed system |
US6248726B1 (en) * | 1985-06-22 | 2001-06-19 | M L Laboratories Plc | Method of peritoneal dialysis using glucose polymer solutions |
GB8521712D0 (en) * | 1985-08-31 | 1985-10-02 | Giltech Ltd | Solution for peritoneal dialysis |
DE3683583D1 (en) * | 1985-09-10 | 1992-03-05 | Res Corp Technologies Inc | OSMOTIC AGENTS FOR PERITONEAL DIALYSIS. |
US4976683A (en) * | 1986-06-20 | 1990-12-11 | Abbott Laboratories | Peritoneal dialysis method |
GR870129B (en) * | 1987-01-27 | 1987-02-04 | Giatzidis Ippokratis | Stable bicarbonate - glycylglycine dialysate for hemodialysis and peritoneal dialysis |
DE3812525C1 (en) * | 1988-04-15 | 1989-06-22 | Fresenius Ag, 6380 Bad Homburg, De | |
DE3821043A1 (en) | 1988-06-22 | 1989-12-28 | Fresenius Ag | DIALYZER AND SPUEL SOLUTION FOR INTRAPERITONEAL ADMINISTRATION |
JP2724597B2 (en) * | 1988-09-22 | 1998-03-09 | 日本精化株式会社 | Purification method of alkyl glycosides |
JPH02304026A (en) | 1989-05-16 | 1990-12-17 | Morishita Pharmaceut Co Ltd | Liquid for peritoneal lavage |
AU627309B2 (en) | 1989-05-26 | 1992-08-20 | Terumo Kabushiki Kaisha | Preparation for blood dialysis and method for production thereof |
SE505967C2 (en) * | 1990-10-15 | 1997-10-27 | Gambro Ab | The respective method for preparing a medical solution, for example a dialysis solution |
JP2722131B2 (en) | 1990-10-16 | 1998-03-04 | 森永乳業株式会社 | Peritoneal dialysate |
DE69215359T2 (en) * | 1991-02-20 | 1997-04-03 | Cultor Oy | REDUCED POLYDEXTROSE |
DE4123001A1 (en) | 1991-07-11 | 1993-01-14 | Laevosan Gmbh & Co Kg | PHARMACEUTICAL COMPOSITION FOR PERITONEAL DIALYSIS |
SE9103395D0 (en) * | 1991-11-18 | 1991-11-18 | Gambro Ab | SYSTEM USING ENSTERIL MEDICAL SOLUTION CONTAINING GLUCOSE OR GLUCOSE-LIKE SUBSTANCES AND A SOLUTION INTENDED FOR THIS SYSTEM |
US5616248A (en) * | 1992-04-06 | 1997-04-01 | Schal; Wilfried | Method for the preparation of hemodialysis fluids containing bicarbonate |
DE4242926C2 (en) * | 1992-12-18 | 1994-12-15 | Fresenius Ag | Dialysis solution for peritoneal dialysis |
IT1263967B (en) * | 1993-02-24 | 1996-09-05 | SOLUTIONS FOR PERITONEAL DIALYSIS | |
US5436232A (en) * | 1994-01-07 | 1995-07-25 | Laevosan-Gesellschaft Mbh | Pharmaceutical composition for peritoneal dialysis |
JPH07252137A (en) | 1994-02-21 | 1995-10-03 | Terumo Corp | Saccharides-containing electrolyte solution |
GB9411009D0 (en) * | 1994-06-02 | 1994-07-20 | Giltech Ltd | Dialysis fluid |
JP3647898B2 (en) | 1994-06-28 | 2005-05-18 | 味の素ファルマ株式会社 | Sodium bicarbonate dialysis agent and method for producing the same |
SE510030C2 (en) * | 1995-08-08 | 1999-04-12 | Gambro Ab | Method of mixing sterile medical solution and container for carrying out the procedure |
CA2155910C (en) * | 1995-08-11 | 1999-12-14 | George Wu | Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis |
JPH0987182A (en) | 1995-09-27 | 1997-03-31 | Terumo Corp | Neutral peritoneal dialysis fluid |
SE9600631D0 (en) * | 1996-02-20 | 1996-02-20 | Gambro Ab | Use of a solution containing glucose for peritonial dialysis having reduced formation of AGE products |
JPH1094598A (en) * | 1996-07-31 | 1998-04-14 | Baxter Internatl Inc | Peritoneal dialysis liquid |
DE19631124A1 (en) * | 1996-08-01 | 1998-02-05 | Fresenius Medical Care De Gmbh | Process for the preparation of an infusion or dialysis solution containing bicarbonate |
GB9714218D0 (en) | 1997-07-04 | 1997-09-10 | Allied Therapeutics Ltd | Peritoneal dialysis fluid |
SE9703775L (en) | 1997-10-16 | 1999-04-17 | Pharmalink Baslaekemedel Ab | Preparation of glucose-containing sterial solutions |
ATE316383T1 (en) * | 1998-05-21 | 2006-02-15 | Nipro Corp | ALBUMIN CONTAINING SOLUTION FOR PERITONEAL DIALYSIS |
DE69929555T8 (en) * | 1998-06-17 | 2007-05-31 | Nipro Corp. | Use of a liquid for the preparation of a dialysis solution for continuous recirculating peritoneal dialysis |
JP2000037452A (en) | 1998-07-21 | 2000-02-08 | Terumo Corp | Peritoneum dialysis fluid |
SE521219C2 (en) * | 1998-10-23 | 2003-10-14 | Gambro Ab | Method and apparatus for reducing the degradation of heat sensitive components in medical substances during heat sterilization |
JP4284737B2 (en) | 1999-02-26 | 2009-06-24 | 株式会社ジェイ・エム・エス | Neutral peritoneal dialysis solution |
US6251437B1 (en) * | 1999-07-13 | 2001-06-26 | Minntech Corporation | Liquid/powder acid concentrate for dialysate and a method of making the same |
CZ303870B6 (en) | 1999-10-11 | 2013-06-05 | Sigma-Tau Industrie Farmaceutiche Riunite S. P. A. | Utilization of L-carnitine and alkanoyl derivatives thereof as osmotic compositions in solution for medicinal application |
US20030202958A1 (en) * | 1999-10-15 | 2003-10-30 | Strickland Alan D. | Dialysis solution including polyglycol osmotic agent |
WO2002049694A2 (en) * | 2000-12-20 | 2002-06-27 | Dialysis Solutions Inc. | Sterile bicarbonate-free dialysis concentrate solutions |
US6787039B2 (en) * | 2001-01-26 | 2004-09-07 | Degussa Ag | Amino acid composition for hemodialysis |
JP2002308782A (en) | 2001-02-06 | 2002-10-23 | Otsuka Pharmaceut Factory Inc | Method for producing bicarbonate solution |
JP2002282354A (en) | 2001-03-27 | 2002-10-02 | Jms Co Ltd | Liquid for peritoneal dialysis |
GB0108359D0 (en) | 2001-04-03 | 2001-05-23 | Allied Therapeutics Ltd | Peritoneal dialysis fluid |
JP2005510581A (en) * | 2001-04-10 | 2005-04-21 | ダニスコ・ユーエスエー・インコーポレーテッド | Polymerization of monosaccharides and disaccharides using monocarboxylic acids and lactones. |
WO2003013553A1 (en) | 2001-08-10 | 2003-02-20 | Van Dyck Diaz Rodolfo Candelar | Dialysis solution formula and gastrointestinal dialysis method |
DE10217356B4 (en) | 2002-04-18 | 2012-03-29 | Fresenius Medical Care Deutschland Gmbh | Solution for peritoneal dialysis |
-
1998
- 1998-12-04 US US09/206,063 patent/US6770148B1/en not_active Expired - Fee Related
-
1999
- 1999-11-18 ES ES99960509T patent/ES2284281T3/en not_active Expired - Lifetime
- 1999-11-18 WO PCT/US1999/027456 patent/WO2000033851A1/en active IP Right Grant
- 1999-11-18 DK DK99960509T patent/DK1051183T3/en active
- 1999-11-18 AT AT99960509T patent/ATE356627T1/en not_active IP Right Cessation
- 1999-11-18 DE DE69935498T patent/DE69935498T2/en not_active Expired - Lifetime
- 1999-11-18 JP JP2000586342A patent/JP4338317B2/en not_active Expired - Fee Related
- 1999-11-18 ID IDW20001692A patent/ID27897A/en unknown
- 1999-11-18 CN CNB998026840A patent/CN1150903C/en not_active Expired - Fee Related
- 1999-11-18 BR BR9909095-3A patent/BR9909095A/en active Search and Examination
- 1999-11-18 EP EP99960509A patent/EP1051183B1/en not_active Expired - Lifetime
- 1999-11-18 CA CA002319561A patent/CA2319561A1/en not_active Abandoned
- 1999-11-18 KR KR1020007008455A patent/KR100597931B1/en not_active IP Right Cessation
- 1999-11-18 MX MXPA00008653A patent/MXPA00008653A/en not_active IP Right Cessation
- 1999-11-18 AU AU17384/00A patent/AU762933B2/en not_active Ceased
- 1999-11-30 TW TW088120899A patent/TW555561B/en not_active IP Right Cessation
- 1999-12-01 AR ARP990106117A patent/AR021515A1/en not_active Application Discontinuation
- 1999-12-03 CO CO99076224A patent/CO5150157A1/en unknown
-
2001
- 2001-06-15 US US09/882,187 patent/US20010044424A1/en not_active Abandoned
- 2001-09-26 HK HK01106795A patent/HK1036014A1/en not_active IP Right Cessation
-
2004
- 2004-04-14 US US10/824,549 patent/US7208479B2/en not_active Expired - Fee Related
-
2008
- 2008-10-03 JP JP2008259107A patent/JP2009019060A/en not_active Withdrawn
-
2009
- 2009-09-24 JP JP2009219817A patent/JP5286208B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0207676A2 (en) * | 1985-06-22 | 1987-01-07 | M L Laboratories Plc | Polymers for use in continuous peritoneal dialysis |
EP0861661A2 (en) * | 1994-01-21 | 1998-09-02 | Baxter International Inc. | Method of providing an osmotic agent for a peritoneal dialysis solution |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004022602A1 (en) * | 2002-08-16 | 2004-03-18 | Fresenius Kabi Deutschland Gmbh | Highly branched, unsubstituted or low-substituted starch products, dialysis solution and plasma expander containing the same, and the use thereof |
US7550446B2 (en) | 2002-08-16 | 2009-06-23 | Fresenius Kabi Deutschland Gmbh | Highly branched, unsubstituted or low-substituted starch products, dialysis solution and plasma expander containing the same, and the use thereof |
WO2011113608A1 (en) * | 2010-03-19 | 2011-09-22 | Fresenius Medical Care Deutschland Gmbh | Esterified polysaccharide osmotic agents |
WO2013034292A1 (en) * | 2011-09-07 | 2013-03-14 | Fresenius Medical Care Deutschland Gmbh | Pharmaceutical compositions containing carboxylated starch |
US9283246B2 (en) | 2011-09-07 | 2016-03-15 | Fresenius Medical Care Deutschland Gmbh | Pharmaceutical compositions containing carboxylated starch |
WO2016066672A1 (en) * | 2014-10-31 | 2016-05-06 | Fresenius Medical Care Deutschland Gmbh | Pharmaceutical compositions containing steviosides |
US10213452B2 (en) | 2014-10-31 | 2019-02-26 | Fresenius Medical Care Deutschland Gmbh | Pharmaceutical compositions containing steviosides |
Also Published As
Publication number | Publication date |
---|---|
AU1738400A (en) | 2000-06-26 |
US20040192648A1 (en) | 2004-09-30 |
US6770148B1 (en) | 2004-08-03 |
CA2319561A1 (en) | 2000-06-15 |
JP5286208B2 (en) | 2013-09-11 |
US20010044424A1 (en) | 2001-11-22 |
BR9909095A (en) | 2000-12-05 |
HK1036014A1 (en) | 2001-12-21 |
DE69935498D1 (en) | 2007-04-26 |
MXPA00008653A (en) | 2005-12-01 |
ATE356627T1 (en) | 2007-04-15 |
JP2002531226A (en) | 2002-09-24 |
ID27897A (en) | 2001-05-03 |
DE69935498T2 (en) | 2007-11-29 |
EP1051183A1 (en) | 2000-11-15 |
KR100597931B1 (en) | 2006-07-13 |
KR20010040586A (en) | 2001-05-15 |
US7208479B2 (en) | 2007-04-24 |
JP2009019060A (en) | 2009-01-29 |
TW555561B (en) | 2003-10-01 |
ES2284281T3 (en) | 2007-11-01 |
CO5150157A1 (en) | 2002-04-29 |
JP2010001309A (en) | 2010-01-07 |
CN1150903C (en) | 2004-05-26 |
DK1051183T3 (en) | 2007-05-07 |
JP4338317B2 (en) | 2009-10-07 |
EP1051183B1 (en) | 2007-03-14 |
CN1290170A (en) | 2001-04-04 |
AU762933B2 (en) | 2003-07-10 |
AR021515A1 (en) | 2002-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5286208B2 (en) | Peritoneal dialysis solution containing modified icodextrin | |
WO2004058277A1 (en) | Biocompatible dialysis fluids containing icodextrins | |
JPH024427A (en) | Membrane for dialysis of blood | |
EP0914093B1 (en) | Use of a solution comprising glucose for peritoneal dialysis having reduced formation of age products | |
EP0078832A1 (en) | Dialysis solution containing glycerol. | |
RU2118531C1 (en) | Pharmaceutical composition for peritoneal dialysis | |
US7550446B2 (en) | Highly branched, unsubstituted or low-substituted starch products, dialysis solution and plasma expander containing the same, and the use thereof | |
US6156797A (en) | Peritoneal dialysis solution | |
US5436232A (en) | Pharmaceutical composition for peritoneal dialysis | |
WO2007013123A1 (en) | Cyclodextrins for blood detoxification | |
US11498939B2 (en) | Glucose polymers for peritoneal dialysis | |
JP3242675B2 (en) | Dialysis membrane for hemodialysis | |
JPH0871146A (en) | Peritoneum dialyzing liquid containing cyclodextrin or derivative thereof | |
JPH1094598A (en) | Peritoneal dialysis liquid | |
JP2002282354A (en) | Liquid for peritoneal dialysis | |
WO2018100290A1 (en) | Novel compounds for peritoneal dialysis | |
JP2001181179A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99802684.0 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2000 17384 Country of ref document: AU Kind code of ref document: A |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN ID IN JP KR MX SG |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2000/00089/DE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 17384/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999960509 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2000 586342 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2319561 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007008455 Country of ref document: KR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/008653 Country of ref document: MX |
|
WWP | Wipo information: published in national office |
Ref document number: 1999960509 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007008455 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 17384/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007008455 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999960509 Country of ref document: EP |